Afatinib in squamous cell carcinoma of the head and neck

References

• Normanno N, De LA, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006 Jan 17;366(1):2–16.
   PubMed Web of Science ®Google Scholar
• Agulnik M. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol. 2012 Dec;29(4):2481–2491.
   PubMed Web of Science ®Google Scholar
• Pectasides E, Rampias T, Kountourakis P, et al. Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clin Cancer Res. 2011 May 1;17(9):2947–2954.
   PubMed Web of Science ®Google Scholar
• Specenier P, Vermorken JB. Cetuximab: its unique place in head and neck cancer treatment. Biologics. 2013;7:77–90.
   PubMedGoogle Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567–578.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21–28.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116–1127.
   PubMed Web of Science ®Google Scholar
• Genova C, Rijavec E, Barletta G, et al. Afatinib for the treatment of advanced non-small-cell lung cancer. Expert Opin Pharmacother. 2014 Apr;15(6):889–903.
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 7;27(34):4702–4711.
   PubMed Web of Science ®Google Scholar
• Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839–844.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev. 2011 Oct;37(6):456–464.
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007 Mar;7(3):169–181.
   PubMed Web of Science ®Google Scholar
• Suda K, Onozato R, Yatabe Y, et al. EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol. 2009 Jan;4(1):1–4.
   PubMed Web of Science ®Google Scholar
• Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012 Nov;343(2):342–350.
   PubMed Web of Science ®Google Scholar
• 2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002280/WC500152392.pdf. Ref Type: Online Source.
   Google Scholar
• Young NR, Soneru C, Liu J, et al. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol. 2015 Dec;10(4):501–508.
   PubMed Web of Science ®Google Scholar
• Schutze C, Dorfler A, Eicheler W, et al. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol. 2007 May;183(5):256–264.
   PubMed Web of Science ®Google Scholar
• Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012 Apr;69(4):1051–1061.
   PubMed Web of Science ®Google Scholar
• Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010 Sep 1;28(25):3965–3972.
   PubMed Web of Science ®Google Scholar
• Freiwald M, Schmid U, Fleury A, et al. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemother Pharmacol. 2014 Apr;73(4):759–770.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Fayette J, Cupissol D, et al. A randomized, open-label, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: final data. Eur Arch Otorhinolaryngol. 2012;269(4):1374.
   Google Scholar
• Marshall J, Hwang J, Eskens FA, et al. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs. 2013 Apr;31(2):399–408.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Mendelson DS, Gross M, et al. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Apr;31(2):409–416.
   PubMed Web of Science ®Google Scholar
• Eskens FA, Mom CH, Planting AS, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008 Jan 15;98(1):80–85.
   PubMed Web of Science ®Google Scholar
• Molife LR, Rudman SM, Alam S, et al. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemother Pharmacol. 2013 Dec;72(6):1213–1222.
   PubMed Web of Science ®Google Scholar
• Shibata Y, Chiba M. The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib. Drug Metab Dispos. 2015 Mar;43(3):375–384.
   PubMed Web of Science ®Google Scholar
• Schnell D, Buschke S, Fuchs H, et al. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemother Pharmacol. 2014 Aug;74(2):267–275.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Rottey S, Ehrnrooth E, et al. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Ann Oncol. 2013 May;24(5):1392–1400.
   PubMed Web of Science ®Google Scholar
• Chung CH, Rudek MA, Kang H, et al. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral Oncol. 2016;53:54–59.
   Web of Science ®Google Scholar
• Awada AH, Dumez H, Hendlisz A, et al. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Invest New Drugs. 2013 Jun;31(3):734–741.
   PubMed Web of Science ®Google Scholar
• Marshall J, Shapiro GI, Uttenreuther-Fischer M, et al. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Future Oncol. 2013 Feb;9(2):271–281.
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Ahn MJ, Dickgreber NJ, et al. Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl): abstr 8053.
   Google Scholar
• Seiwert TY, Fayette J, Cupissol D, et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2014 Sep;25(9):1813–1820.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Licitra LF, Haddad RI, et al. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC Cancer. 2014;14:473.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May;16(5):583–594.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Licitra LF, Fayette J, et al. Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1). J Clin Oncol. 2015;33(suppl): abstract 6023.
   Google Scholar
• Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res. 2011 Sep 15;17(18):5935–5944.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Smit EF, Groen HJ, et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov. 2014 Sep;4(9):1036–1045.
   PubMed Web of Science ®Google Scholar
• Gazzah A, Boni V, Soria JC, et al. Phase Ib study of afatinib plus standard-dose cetuximab in patients (pts) with advanced solid tumors. J Clin Oncol. 2015;33(suppl):abstr 2536.
   Google Scholar
• Burtness B, Bourhis JP, Vermorken JB, et al. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials. 2014;15:469.
   PubMed Web of Science ®Google Scholar
• 2016 Available from: https://clinicaltrials.gov/ct2/results?term=afatinib+head+and+neck+cancer&Search=Search. Ref Type: Online Source
   Google Scholar
• FDA approves afatinib for advanced lung cancer. Oncology (Williston Park). 2013 August;27(8):813–814.
   Web of Science ®Google Scholar
• 2016 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/192013/201292s000lbl.pdf. Ref Type: Online Source.
   Google Scholar